Brian Culley
Vermögen: 339 836 $ am 31.05.2026
Vermögen: 339 836 $ am 31.05.2026
Brian M.
Culley is currently President, Chief Executive Officer, CAO & Director at Lineage Cell Therapeutics, Inc. since 2022 and Chief Executive Officer at Asterias Biotherapeutics, Inc. since 2019.
Formerly, Mr. Culley was Chief Executive Officer & Director at Mast Therapeutics, Inc. from 2011 to 2017, Chief Executive Officer at Manuka, Inc. from 2017 to 2018, Chief Executive Officer & Director at Savara, Inc., Director at Orphagen Pharmaceuticals from 2017 to 2022, Director-Business Development & Marketing at iTherX Pharmaceuticals, Inc. from 2002 to 2004, and Licensing & Marketing Associate at the University of California, Berkeley from 1999 to 2000.
Education includes undergraduate studies at Boston College, graduate studies at the University of California, Santa Barbara, and an MBA from Johnson Graduate School of Management.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 20.04.2026 | 255’516 ( 0.1% ) | 339 836 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| LINEAGE CELL THERAPEUTICS, INC. | Vorstandsvorsitzender | 17.09.2018 |
| ASTERIAS BIOTHERAPEUTICS INC | Vorstandsvorsitzender | 08.03.2019 |
| Unternehmen | Position | Ende |
|---|---|---|
Orphagen Pharmaceuticals
Orphagen Pharmaceuticals Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Direktor/Vorstandsmitglied | 01.12.2022 |
| MANUKA, INC. | Vorstandsvorsitzender | 17.09.2018 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies for serious or life-threatening diseases with significant unmet needs | Vorstandsvorsitzender | 28.04.2017 |
| SAVARA INC. | Vorstandsvorsitzender | 27.04.2017 |
iTherX Pharmaceuticals, Inc.
iTherX Pharmaceuticals, Inc. Medical DistributorsDistribution Services Engages in the discovery and development of drugs and therapies | Vertrieb & Marketing | 01.01.2004 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development of therapeutic products for retinal & neurological diseases and disorders and oncology | Health Technology |
iTherX Pharmaceuticals, Inc.
iTherX Pharmaceuticals, Inc. Medical DistributorsDistribution Services Engages in the discovery and development of drugs and therapies | Distribution Services |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies for serious or life-threatening diseases with significant unmet needs | Health Technology |
Asterias Biotherapeutics, Inc.
Asterias Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops and commercializes regenerative medicine for neurology and oncology applications | Health Technology |
Boston College
Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Santa Barbara
University of California, Santa Barbara Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Johnson Graduate School of Management
Johnson Graduate School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Orphagen Pharmaceuticals
Orphagen Pharmaceuticals Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Health Technology |
Manuka, Inc.
Manuka, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Savara, Inc.
Savara, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals to treat respiratory diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen